Literature DB >> 9724386

Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy.

G Paganelli1, R Orecchia, B Jereczek-Fossa, C Grana, M Cremonesi, F De Braud, N Tradati, M Chinol.   

Abstract

The prognosis of patients with locally advanced head and neck cancer remains grim due to poor locoregional tumour control. In the attempt to eradicate residual disease, various novel modalities have been tested, among which radioimmunotherapy (RIT) has shown some potential. We present a case of locally advanced oropharyngeal carcinoma successfully treated with a combination of various treatments including surgery, radio-chemotherapy and three-step RIT, with the avidin-biotin pretargeting system. A partial tumour response was achieved after surgery and radio-chemotherapy; persistent disease was documented at computed tomography (CT), ultrasound (US) and immunoscintigraphy (ISG) 10 weeks after the end of chemo-radiotherapy. The good correlation between the tracer localization in the scintigraphic images and residual mass visualized at CT suggested the application of three-step RIT using systemic administration of yttrium-90 (py) biotin. At present, 17 months after RIT, the patient is alive with no evidence of disease as documented by magnetic resonance imaging (MRI) and US. This is the first case of complete clinical remission of a head and neck carcinoma induced by combined treatment including pretargeted RIT with 90Y-biotin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9724386     DOI: 10.1007/s002590050305

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  8 in total

1.  Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?

Authors:  Giovanni Paganelli; Marco Chinol
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-30       Impact factor: 9.236

2.  Antibody-based cancer therapies: back to "polyclonals"?

Authors:  Giovanni Paganelli; Rita De Santis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-17       Impact factor: 9.236

3.  Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT).

Authors:  Nicoletta Urbano; Stefano Papi; Mauro Ginanneschi; Rita De Santis; Silvia Pace; Ragnar Lindstedt; Liliana Ferrari; Sunju Choi; Giovanni Paganelli; Marco Chinol
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-06       Impact factor: 9.236

4.  90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.

Authors:  Guozheng Liu; Shuping Dou; Yuxia Liu; Yuzhen Wang; Mary Rusckowski; Donald J Hnatowich
Journal:  Bioconjug Chem       Date:  2011-11-03       Impact factor: 4.774

5.  Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.

Authors:  John M Pagel; Nathan Hedin; Lacey Drouet; Brent L Wood; Anastasia Pantelias; Yukang Lin; Donald K Hamlin; D Scott Wilbur; Ajay K Gopal; Damian Green; Frederick R Appelbaum; Oliver W Press
Journal:  Blood       Date:  2007-11-27       Impact factor: 22.113

6.  Improvement of radioimmunotherapy using pretargeting.

Authors:  Eric Frampas; Caroline Rousseau; Caroline Bodet-Milin; Jacques Barbet; Jean-Francois Chatal; Françoise Kraeber-Bodéré
Journal:  Front Oncol       Date:  2013-06-20       Impact factor: 6.244

7.  Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study.

Authors:  C Grana; M Chinol; C Robertson; C Mazzetta; M Bartolomei; C De Cicco; M Fiorenza; M Gatti; P Caliceti; G Paganelli
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640

Review 8.  Therapeutic Applications of Pretargeting.

Authors:  Marjolein Verhoeven; Yann Seimbille; Simone U Dalm
Journal:  Pharmaceutics       Date:  2019-09-01       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.